Filing Details

Accession Number:
0001181431-14-004413
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-30 16:42:29
Reporting Period:
2014-01-29
Filing Date:
2014-01-30
Accepted Time:
2014-01-30 16:42:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1325879 Aveo Pharmaceuticals Inc AVEO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1486359 Jeno Gyuris C/O Aveo Pharmaceuticals, Inc.
650 E. Kendall Street
Cambridge MA 02142
Svp, Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-01-29 3,200 $0.00 99,245 No 4 D Direct
Common Stock Disposition 2014-01-30 5,430 $1.64 93,815 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 D Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right-to-buy) Acquisiton 2014-01-29 75,000 $0.00 75,000 $1.77
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
75,000 2024-01-29 No 4 A Direct
Footnotes
  1. Shares underlying such disposition to the issuer were forfeited by the reporting person pursuant to the terms of an award of restricted stock granted to the reporting person on June 26, 2013 in connection with the determination of the issuer's Compensation Committee that certain specified strategic performance objectives were not met.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2013, which was implemented to cover taxable events related to the partial vesting of certain restricted stock.
  3. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.69, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
  4. This option vests in equal monthly installments from January 1, 2014 through January 1, 2018.